Steven Pieper Sells 5,000 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Steven Pieper sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $8.50, for a total transaction of $42,500.00. Following the sale, the insider owned 1,356,053 shares of the company’s stock, valued at approximately $11,526,450.50. The trade was a 0.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Pieper also recently made the following trade(s):

• On Wednesday, August 12th, Steven Pieper sold 5,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.50, for a total transaction of $42,500.00.
• On Tuesday, July 7th, Steven Pieper sold 27,600 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.52, for a total transaction of $235,152.00.
• On Monday, July 6th, Steven Pieper sold 17,400 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.50, for a total transaction of $147,900.00.

Xeris Biopharma Trading Down 0.1%

Shares of NASDAQ XERS traded down $0.01 during midday trading on Tuesday, reaching $8.43. 1,144,088 shares of the stock were exchanged, compared to its average volume of 1,849,041. The stock has a market capitalization of $1.54 billion, a P/E ratio of -76.64 and a beta of 0.66. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.02 and a current ratio of 1.45. The company has a 50 day simple moving average of $8.32 and a 200 day simple moving average of $6.93. Xeris Biopharma Holdings, Inc. has a twelve month low of $5.25 and a twelve month high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). The business had revenue of $92.10 million during the quarter, compared to analyst estimates of $90.12 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. As a group, equities analysts expect that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current year.

Hedge Funds Weigh In On Xeris Biopharma

Several large investors have recently made changes to their positions in the stock. BlackRock Inc. purchased a new position in shares of Xeris Biopharma during the 2nd quarter worth approximately $115,042,000. Legal & General Group Plc acquired a new stake in Xeris Biopharma in the 2nd quarter valued at approximately $15,941,000. Parkman Healthcare Partners LLC purchased a new stake in Xeris Biopharma in the second quarter valued at approximately $14,316,000. UBS Group AG raised its position in Xeris Biopharma by 682.4% in the third quarter. UBS Group AG now owns 1,782,734 shares of the company’s stock valued at $14,511,000 after purchasing an additional 1,554,869 shares during the period. Finally, Bank of America Corp DE purchased a new stake in Xeris Biopharma in the second quarter valued at approximately $11,065,000. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on XERS. Barclays upped their price target on Xeris Biopharma from $9.00 to $12.00 and gave the company an “overweight” rating in a research note on Thursday, August 20th. Wall Street Zen downgraded Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings downgraded Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $12.00.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.